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RADIATION-STIMULATED EPIGENETIC REPROGRAMMING OF 
ADAPTIVE-RESPONSE GENES IN THE LUNG: AN EVOLUTIONARY GIFT 
FOR MOUNTING ADAPTIVE PROTECTION AGAINST LUNG CANCER
Bobby R. Scott, Steven A. Belinsky, Shuguang Leng, Yong Lin, Julie A. Wilder, and
Leah A. Damiani  Lovelace Respiratory Research Institute, Albuquerque, NM
 Humans are continuously exposed to low-level ionizing radiation from natural
sources. However, harsher radiation environments persisted during our planet’s early
years and mammals survived via an evolutionary gift - a system of radiation-induced natural
protective measures (adaptive protection). This system includes antioxidants, DNA repair, apop-
tosis of severely damaged cells, epigenetically regulated apoptosis (epiapoptosis) pathways
that selectively remove precancerous and other aberrant cells, and immunity against can-
cer. We propose a novel model in which the protective system is regulated at least in part
via radiation-stress-stimulated epigenetic reprogramming (epireprogramming) of adaptive-response
genes. High-dose radiation can promote epigenetically silencing of adaptive-response
genes (episilencing), for example via promoter-associated DNA and/or histone methylation
and/or histone deacetylation. Evidence is provided for low linear-energy-transfer (LET)
radiation-activated natural protection (ANP) against high-LET alpha-radiation-induced
lung cancer in plutonium-239 exposed rats and radon-progeny-exposed humans. Using a
revised hormetic relative risk model for cancer induction that accounts for both epige-
netic activation (epiactivation) and episilencing of genes, we demonstrate that, on average,
>80% of alpha-radiation-induced rat lung cancers were prevented by chronic, low-rate
gamma-ray ANP. Interestingly, lifetime exposure to residential radon at the Environmental
Protection Agency’s action level of 4 pCi L–1 appears to be associated with on average a >
60% reduction in lung cancer cases, rather than an increase. We have used underlined
italics to indicate newly introduced terminology.
Keywords: radiation hormesis, adaptive response, epigenetic reprogramming
INTRODUCTION
An important and essential characteristic of biological organisms is
their ability to persist in the face of repeated challenging conditions.
Every human alive today owes their existence to the billions of genera-
tions of progenitors that survived and reproduced in spite of the previous
challenging environmental and other conditions (Lenski et al. 2006). The
initial emergence of mammalian life on earth took place in an environ-
ment with higher but unknown natural background levels of radiation;
even, so mammals, including humans, survived via evolutionarily-derived
adaptive responses to the harsher natural radiation environment. The
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defense repertoire for humans ultimately comprised all levels of the bio-
logical hierarchy—from the molecular and biochemical level to the cel-
lular and tissue level to the organ and organ system level (Trosko 1998).
Although natural background radiation levels are much lower today,
these evolutionarily derived, adaptive-response phenotypes can be
invoked by ionizing radiation doses and dose rates somewhat higher than
current natural levels (i.e., low doses and dose rates) and are thought to
be regulated at least in part epigenetically (Koturbash et al. 2006).
Epigenetic Regulation of Genes
The term epigenetic refers to a heritable change in the pattern of gene
activity that is mediated by mechanisms other than alterations in the pri-
mary nucleotide sequence of a specified gene (Bird 2002; Russo et al.
1996). Epigenetic regulation (epiregulation) of gene activity is widespread
in the genome of eukaryotic cells and can lead to silencing (episilencing)
or activation (epiactivation) of gene expression. Epireprogramming is used in
this paper to represent both epiactivation and episilencing. We have used
underlined italics to indicate newly-introduced terminology. This con-
vention is used throughout the paper.
The control of transcription is regulated by transcription factors, by
changes in the methylation status of DNA (the methylation of cytosine
residues at 5’ carbon), and by modifications in chromatin (e.g., histone
methylation, acetylation, phosphorylation and ubiquitination)
(Karpinets and Foy 2005). DNA and histone methylation and histone
deacetylation result in a compact chromatin configuration that silences
entire regions of DNA. For suppressor gene promoters, the compact
chromatin topology restricts the access of the polymerase II complex to
regulatory sequence domains, thereby inhibiting tumor suppressor tran-
scription (Karpinets and Foy 2005). 
Hypermethylation of gene promoters is a mechanism of long-term gene
episilencing. However, episilencing can be reversed by demethylation of DNA. 
Demethylation of DNA has been suggested to be involved in DNA
repair (Reik 2007) and along with p53 (Camphausen et al. 2003) has been
implicated in high-dose radiation abscopal effects (Koturbash et al. 2006).
DNA repair is important in adaptive responses of mammalian cells to
genotoxic threats, and epigenetic changes have important roles in acti-
vating and directing DNA repair pathways; however, mechanisms that
govern epireprogramming during DNA repair and replication are not
fully understood (Leng et al. 2008).
Methylation of CpG islands in promoter regions of some genes in
colon cancer appears to increase with age (Issa et al. 1994). This suggests
that life history can impact on the epigenetic profile. 
Many genes that are epigenetically reprogrammed via hypermethyla-
tion have classic tumor suppressor functions. This includes the VHL gene
2
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in renal cancer, the CDKN2A (p16) gene in many types of cancer, and the
mismatch-repair gene MLH1 in colorectal and other cancers (Herman
and Baylin 2003). We consider any DNA repair or tumor suppressor gene
that is activated by low-dose radiation to be an adaptive-response gene.
However, new research is needed to clarify any roles that tumor suppres-
sor genes may have in mounting the radiation adaptive responses that
suppress cancer occurrence.
Gene episilencing (via promoter hypermethylation) involves the cyto-
sine DNA methyltransferases 1, 3a, and 3b (DNMTs) which act via de novo
methylation and recruitment of chromatin remodeling proteins
(Damiani et al. 2008). DNMT1 which has both maintenance and de novo
methyltransferase activity, is responsible for approximately 90% of the
methyltransferase activity in mammalian cells. The DNMT1 protein is
rapidly recruited to sites of DNA damage where it participates in de novo
methylation and is over-expressed in lung and several other cancers
(Damiani et al. 2008). Because significant DNA damage is caused by mod-
erate and high doses of radiation, DNMT1 may participate in inhibiting
radiation adaptive-response phenotypes. 
High doses and dose rates of radiation are proposed to lead to silenc-
ing of adaptive-response genes via mutation induction and/or epirepro-
gramming of promoters (e.g., promoter hypermethylation and/or his-
tone deacetylation). This allows for what others have called a two-hit
model for inactivation of both gene copies (Knudson 2001). However,
dose-related multiple events (e.g., hypermethylation) are implicated for
single-gene-copy silencing via methylation. Thus, the “two-hit” terminolo-
gy appears inappropriate. 
Low doses and dose rates of low-LET radiation are proposed to lead
to epigenetic changes (up-regulation of adaptive-response genes, e.g., via
acetylation) that facilitate managing future threatening genetic hazards.
Adaptive-response genes (e.g., tumor suppressor p53) can be stabilized
and activated in response to cellular stress (e.g., low dose radiation)
through post-translational modifications that include acetylation (Ito et
al. 2002). P300/CBP-mediated acetylation of p53 is, however, negatively
regulated by MDM2.
Low-Dose-Radiation Stimulated Protective Apoptosis Medicated (PAM)
Process
Low doses and dose rates of low-linear-energy-transfer (LET) radia-
tion (e.g., X-rays, gamma rays, and beta radiation) above a stochastic
threshold stimulate intracellular and intercellular signaling that leads to
activated natural protection (ANP) against cancer and other genomic-
instability-associated diseases (Scott 2005; Scott and Di Palma 2006).
Pathways that include induced p53-dependent high-fidelity DNA repair
along with normal apoptosis (which eliminates seriously damaged cells),
3
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activation of an epigenetic protective apoptosis-mediated (PAM) process
that selectively removes precancerous and other aberrant cells (Scott and
Di Palma 2006), and induced immune functions (Liu 2003, 2007) have
been found to be key components to the low-dose radiation ANP. Here
we refer to the epigenetic PAM process as epiapoptosis. Others have
demonstrated in vitro that reactive oxygen and nitrogen species and spe-
cific cytokines (e.g., transforming growth factor β) are involved in this
natural protection and that signaling to apoptosis is independent of the
p53 gene (Hipp and Bauer 1997; Bauer 2007; Portess et al. 2007).
The PAM process and stimulated immunity (ANP), which are activat-
ed by low doses and dose rates of low-LET radiation, appear to be inhib-
ited by moderate and high doses of radiation as well as by high radiation
dose rates (Scott and Di Palma 2006; Liu 2007). High-LET alpha radia-
tion does not appear to effectively activate the PAM process (Scott et al.
2007). For exposure to neutrons, the gamma-ray component to the dose
appears to activate the PAM process and thereby protect from deleterious
neutron-induced stochastic effects (Rithidech and Scott 2008). The level
of protection appears to increase as the gamma-ray contribution to the
dose increases, which depends on neutron energy (Rithidech and Scott
2008). The PAM process is transient and may not persist for more than a
few tens of hours (Scott and Di Palma 2006).
Genetic Polymorphisms in DNA Repair and Other Adaptive-Response
Genes and their Influence on Radiation Responses
Radiation-induced repair of DNA double-strand breaks (DSB) is
known to require a threshold dose (Rothkamm and Löbrich 2003) that
may vary for different individuals, depending on their genetic character-
istics (Scott 2005). This is supported by the fact that DNA DSB repair
fidelity has been demonstrated to vary for different individuals. A 50%
reduction in the mean level of DNA DSB repair capacity was found
among lymphocytes from cigarette smokers with a high methylation
index, defined as three or more of eight genes methylated in sputum,
compared with smokers with no genes methylated. Single nucleotide
polymorphisms within the MRE11A, CHEK2, XRCC3, DNA-PKc, and NBN
DNA repair genes were highly associated with the methylation index
(Leng et al. 2008). These findings provide indirect evidence for genetic/epigenet-
ic links to susceptibility to genomic stresses such as ionizing radiation. Thus,
genetic variability provides a plausible basis for variability in response to
radiation-induced harm for different individuals. 
When harm is evaluated via endpoints such as mutations and neo-
plastic transformation, stochastic threshold doses (which vary for differ-
ent individuals) are implicated as previously proposed (Scott 2005). The
stochastic thresholds can be protective (e.g., activation of DNA repair) or
deleterious (e.g., inhibition of the PAM process).
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The radiation dose threshold distributions for activating the different
components of adaptive protection (e.g., DNA repair, PAM process,
immunity against cancer) likely differ, but this has not been studied. The
current risk model for radiation-induced cancer developed at our
Institute (Scott and Di Palma 2006) does not allow for different threshold
distributions for the different contributors to adaptive protection. Onsets
and durations of protective signaling are also not addressed. We plan to
address these deficiencies in future research.
Carcinogen-Induced DNA Damage and Related Promoter Episilencing
Carcinogens in cigarette smoke [e.g., benzo(a)pyrene (BAP)] can
directly or indirectly cause single and DSB in DNA. Genotoxic but not
cytotoxic exposure to a DNA damaging agent was associated with reduced
DNA repair capacity and an increased lung cancer risk (Leng et al. 2008).
Mounting evidence suggests that a high prevalence of DNA DSBs could
be partly responsible for the acquisition of aberrant gene promoter
methylation during lung carcinogenesis and influenced by the carcino-
gen dose. For example, the prevalence of promoter hypermethylation of
the cell-cycle-regulating p16 gene was significantly greater (p = 0.03) in
adenocarcinomas from workers occupationally exposed to high levels of
plutonium-239 (239Pu) alpha radiation (an exposure that efficiently pro-
duces DSBs) than in tumors from unexposed smokers after adjusting for
smoking (Belinsky 2004; Belinsky et al. 2004). The prevalence of methy-
lation increased as the total radiation dose (and 239Pu organ burden) to
the lung increased. In addition, a trend (p = 0.08) was seen for an
increase in the number of genes methylated (≥ 2) with increased alpha
radiation dose (and 239Pu organ burden). In studies of rodent lung can-
cer the prevalence of methylation was less for chemicals that mainly pro-
duced DNA single-strand breaks than for alpha radiation (Belinsky 2005).
These findings support the hypothesis that DSB may play an important
role in triggering episilencing of protective genes (e.g., hypermethylation
of tumor suppressor gene promoters). Episilencing of protective genes is
strongly associated with increased risk for cancer (Belinsky 2004).
The steep rise in the lung cancer incidence in humans above the
spontaneous level after moderate and high alpha radiation doses has
been explained on the basis of varying individual-specific thresholds for
suppression of adaptive protection (e.g., suppression of the immune sys-
tem) (Scott and Di Palma 2006). The thresholds appear to be related to
the DNA-damage-associated episilencing of adaptive-response genes.
Immune System’s Contribution to Radiation Adaptation
It is expected that as low doses and dose rate of low-LET radiation
exceed an individual-specific (stochastic) threshold, modulation of the
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pulmonary immune response will occur in a manner to promote apopto-
sis and/or immune-mediated clearance of new premalignant cells, lead-
ing to a reduced lung cancer risk (Liu 2003, 2007). These changes may
manifest as increased numbers or activity of natural killer cells and cyto-
toxic lymphocytes; increased ability of dendrite cells to recognize and
present novel antigens to T cells that in turn induce their proliferation
and cytokine secretion (perhaps favoring Th1 differentiation and inter-
feron-gamma production); or enhanced activation of intracellular signal-
ing molecules (leading to up-regulation of nuclear factor κB and down-
stream gene expression) (Yuan et al. 1992; Wilder and Yuan 1995; Wilder
et al. 1996).
There is evidence for enhanced immune system functioning in rela-
tion to chronic, low-rate exposure to natural background radiation.
Inhabitants of a high natural background area of Iran show a significant
increase of CD69 expression on TCD+ stimulated cells and total serum
IgE, indicating enhanced immune functioning under conditions of pro-
longed low-rate, low-dose, low-LET radiation exposure (Ghiassi-Nejad et
al. 2004). 
Evidence for Novel Adaptive-Response Pathways
Ultra-low radiation doses (below those that stimulate measurable
DNA repair, epiapoptosis, and immune system functioning) in excess of
natural background radiation (evaluated over the exposure period) are
also protective of a subsequent high dose (Day et al. 2007). Thus, addi-
tional components to adaptive protection (a hormetic effect) appear to
be important and may involve epireprogramming of adaptive-response
genes (Karpinets and Foy 2005). 
Recently, it was reported that extended, low-rate gamma-ray exposure
(1–2 mGy) completely inhibited 239Pu alpha radiation-induced lung can-
cer, for doses up to approximately 0.6 Gy (600 mGy), in Wistar rats (Scott
et al. 2008). The protection lasted for more than 1 year after delivery of
the gamma-ray dose, eliminating induced persistent DNA repair, epi-
apoptosis, and immunity as contributors to the persistent protection.
Thus, there appears to be a previously unrecognized, chronic, low-dose,
low-LET radiation-induced protective change in normal cells that is per-
sistent and may involve epigenetic memory because gamma-ray doses of
1–2 mGy when delivered at a very low rate produce little damage to DNA
and do not increase expression of DNA repair or immune system genes
(Rothkamm and Löbrich 2003; Liu 2007). The nature of the persistent
protection brought on by exposure to a low dose of low-LET radiation is
not resolved but may involve an enhanced DNA repair capacity. This is
addressed in the Discussion section of the paper.
In the Wistar rat study discussed, alpha radiation > 10 Gy (10,000 mGy)
in conjunction with a small gamma-ray dose efficiently induced lung can-
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cer. The frequency of lung cancer was not as high as that induced by alpha
radiation alone. This suggests that protection by low-dose, low-LET radia-
tion was partially suppressed by other changes, possibly involving methyla-
tion of adaptive-response genes (Belinsky 2004; Belinsky et al. 2004) as well
as other detrimental epigenetic changes (Karpinets and Foy 2005). 
In this paper we present results of a more detailed analyses of the
Wistar rat lung cancer data, showing that the upper 95% confidence val-
ues on the observed zero cancer incidences are relatively large, suggest-
ing that the level of protection may have been < 100%. New modeling
results are also presented related to lung cancer suppression in associa-
tion with residential exposure to radon progeny. The new results are
based on data from a recent well-designed epidemiological study
(Thompson et al. 2008) and a revised version of an existing dose-response
model (Scott and Di Palma 2006) that accounts for radiation adaptive
responses. In the revised version, radiation-induced lung cancer is linked
to radiation-induced epireprogramming of adaptive-response genes. 
THE NATURAL IONIZING RADIATION ENVIRONMENT
Most members of the public believe that we are normally radiation-
free entities and any amount of radiation is harmful. This is not correct
as radiation is everywhere, including in our bodies (Figure 1). The natu-
ral background ionizing radiation encountered on Earth comes from the
sun (solar radiation), outer space (cosmic rays), and terrestrial sources
(e.g., radionuclides in our environment, homes, and bodies). The main
source of internal radiation is ingested potassium-40 (40K) followed by
carbon-14 (14C). Table 1 lists estimates of the natural radioactivity in the
body of a 70-kg adult human from some of the long-lived radionuclides,
based on information available via the web (ISU 2008). For 40K, there are
about 380 million disintegrations per day, approximately 90% (342 mil-
lion) of which involve emission of beta particles. For proponents of the
linear-no-threshold (LNT) hypothesis that implicates each beta particle
emission as being harmful, there is no scientific basis for such a claim. The fol-
lowing section describes how these millions of beta particle emissions in our
bodies each day may in fact be beneficial to our health.
EARTH’S PREVIOUS HIGHER NATURAL BACKGROUND RADIATION
LEVELS’ EVOLUTIONARY IMPACT ON MAMMALS
Billions of years ago when mammalian life first evolved on Earth, nat-
ural radiation levels were much higher due to the presence of both long-
and short-lived radionuclides (Draganic´ et al. 1990). Since then, all of the
short lived isotopes have decayed. Only those initially-present isotopes
with very long half lives (e.g., > 100 million years) remain along with the
isotopes that formed from the decay of the long-lived isotopes and newly
7
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produced isotopes. Evolutionary changes allowed mammals to cope with
the higher radiation levels that previously existed via radiation adaptation
(Tubiana 2008). The adaptation included acquiring the capability to
correct nuclear DNA damage via a number of repair pathways that
evolved over time and today can be stimulated by beta particle emissions
FIGURE 1. Natural radiation sources: plant, animals, our bodies, soil, rocks, cosmic rays, indoor
radon.
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or secondary electrons (similar to beta particles) produced by gamma
rays. These different repair processes are regulated by both genetic and
epigenetic pathways.
Epiapoptosis (e.g., PAM process) is now considered to protect mam-
mals from stochastic effects of higher natural background radiation lev-
els, and it was probably important to maintaining mammalian life on
Earth through the earlier periods of high natural radiation (Scott 2007).
This is supported by the fact that low-LET radiation levels somewhat
above current natural background levels stimulate the removal of neo-
plastically transformed cells (Redpath et al. 2001), likely via epiapoptosis.
Evolution also gave mammals an additional, apparently longer lasting
type of protection that is stimulated by low doses of low-LET radiation.
This protection relates to stimulating the immune system, which protects
the body from cancer by eliminating precancerous and cancer cells
(Ghiassi-Nejad et al. 2004; Liu 2007).
CURRENT SYSTEM FOR LIMITING HUMAN RADIATION EXPOSURE 
The current system for limiting radiation exposure of humans is
based on the premise that cancer is the major risk from small radiation
doses and cancer risk increases as a linear-no-threshold (LNT) function
of radiation dose (NRC 2006). The LNT model claims that any radiation
dose, no matter how small, causes some cancers among a very large irra-
diated population and that doubling the radiation dose doubles the num-
ber of cancer cases. Thus, from Table 1 it can be inferred based on the
LNT model that the more than 1 million radioactive disintegrations that
take place in our bodies each day produce cancer in some people among
the world population. Whatever this hypothetical number of people is cal-
culated to be, the number of induced cancer cases would be predicted to
double in two days and to further increase with each passing day.
However, the LNT model is empirical, is not based on modern science,
and there are no data to support it in the context of low-level radiation
exposure (Tubiana 2005, 2008; Tubiana et al. 2005).
TABLE 1. Natural radioactivity in the body of a typical 70-kg (150-pound) adult human*
Nuclide Approximate Total Mass Disintegrations per Day
Uranium isotopes 90 micrograms 95 thousand
Thorium isotopes 30 micrograms 9.5 thousand
Potassium-40 17 miligrams 380 million
Radium isotopes 31 picograms 95 thousand
Carbon-14 22 nanograms 320 million
Tritium 0.06 picograms 2 million
Polonium isotopes 0.2 picograms 3.2 million
*Based on information from Idaho State University’s web site (ISU 2008).
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Because the current system of limiting radiation exposure is tied to the
LNT model, demonstrating either a radiation dose threshold for cancer
induction or a decrease in cancer risk as radiation exposure increases
above natural background exposure levels for a range of doses causes major
problems for justifying the continued use of the current LNT-based system. 
There is now abundant evidence that low doses and dose rates of low-
LET radiation (gamma rays, X rays, beta radiation) protect, rather than
harm. Low doses or low dose rates of low-LET radiation have been demon-
strated to do each of the following: (1) protect against spontaneous
genomic damage (Feinendegen 2005; Feinendegen et. al 2007); (2) pro-
tect against spontaneous and high-radiation-dose-induced mutations (Day
et al. 2007); (3) protect against neoplastic transformation (Redpath et al.
2001; Bauer 2007; Portess et al. 2007); (4) protect against high-dose chem-
ical- (Sakai et al. 2003) and alpha-radiation-induced (Sanders 2008; Scott
et al. 2008) cancers; (5) enhance immune system defense against cancer
(Liu 2003; Cuttler 2007); (6) suppresses metastasis of existing cancer (Liu
2007); (7) extend tumor latency period (Mitchel 2007); (8) protect
against diseases other than cancer (Luckey 1991; Sakai 2006), and (9) pro-
tect against heritable mutations and fetal malformation (Boreham et al.
2006). A new study (Mancuso et al. 2008) has yield data showing that a
total-body X-ray dose of 36 mGy suppressed spontaneous brain cancer in
brain-cancer-prone mice, although this feature of the data was apparently
not recognized by the researchers. Epigenetic signaling pathways likely are
important for the indicated radiation adaptive-response phenotypes. Collectively,
the above findings invalidate the LNT model.
LINKING THE HORMETIC RELATIVE RISK MODEL TO
EPIREPROGRAMMING OF ADAPTIVE-RESPONSE GENES
This section focuses on lung cancer associated with combined expo-
sure of the lung to low doses and dose rates of low-LET beta/gamma plus
high-LET alpha radiation. Mathematical relationships are initially pre-
sented for hypothetical groups of people with identical genetic/epige-
netic characteristics. We then address heterogeneous populations over
which such characteristics are allowed to vary. 
Results presented here for beta and gamma radiations also apply to
each of these radiations when evaluated separately. With the current ver-
sion of our stochastic hormetic relative risk (HRR) model, the irradiated
subpopulation is separated into two dose, dose-rate, and genetic/epige-
netic characteristics dependent parts: (1) those that have maximal ANP
and (2) those without ANP. For people with low-LET radiation ANP (a
stochastic quantity), the average cancer relative risk is given by 
RRANP  (1  PROFAC)RRLNT , (2)
10
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where RRANP is the average relative risk for protected individuals and
RRLNT is the relative risk for individuals without ANP and is based on the
LNT assumption. Risk is evaluated relative to an unirradiated genetically
and epigenetically matched population. The protection factor (profac),
whose average over the subpopulation is PROFAC, is allowed to vary for
each individual. 
The PROFAC (subpopulation average) has values from 0 to 1 and here
accounts for prevention of cancer via gamma-ray ANP. PROFAC = 0.25
indicates that cancer would be expected on average to be prevented in 1
of each 4 individuals with radiation ANP for the subpopulation consid-
ered. The PROFAC is allowed to vary over a heterogeneous population.
The relative risk, RRLNT, applies for alpha-radiation-induced lung cancer
and is evaluated based on an LNT function that includes the baseline
(spontaneous) cancer incidence B (Scott 2007):
RRLNT  1  [(1  B)/B]KαDα. (3)
The slope parameter Kα (subpopulation average) is presumed always-pos-
itive for people (subpopulation) with similar genetic/epigenetic charac-
teristics, and Dα is the alpha radiation absorbed dose to the target organ.
Our use of “spontaneous cancer” is quite general and includes all spo-
radic and hereditary cancers not associated with the radiation exposure
of interest.
Equation 2 is used to evaluate cancer RR for combined exposure to
low-LET beta and/or gamma rays and high-LET alpha radiation while
Equation 3 applies to exposure to alpha radiation alone and relates to
doses below those that cause death from acute effects (Scott 2007).
Equation 2 does not apply to high doses and dose rates of low-LET radia-
tion. Also, the PROFAC relates only to the low-LET component of the
dose. Setting PROFAC to zero in Equation 2 yields Equation 3. 
RRLNT should be set to 1 in Equation 2 for exposure only to low doses
and dose rates of low-LET radiation. The average RR is modeled as being
independent of the low-LET radiation dose, taking on values < 1 for doses
above a very low maximum stochastic threshold for ANP. This solution
applies only for low doses and dose rates where epireprogramming of
adaptive-response genes is now presumed to enhance one’s capacity to
prevent cancer occurrence (adaptive protection/hormesis). Both profac
and PROFAC depend on the low-LET radiation dose-rate history and radi-
ation physical characteristics. For very low doses of low-LET radiation,
this protection is expected to be progressively lost as the dose decreases
and RR is expected to correspondingly increase. 
In the original HRR model, DNA repair capacity impacted Kα while
the PAM process and stimulated immunity impacted PROFAC (Scott and
11
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Di Palma 2006). Here, this characteristic is retained because we can also
address deleterious epigenetic changes as follows: changed risk for indi-
viduals with adaptive responses suppressed due to dose-related epirepro-
gramming of promoters can be addressed by reassigning risk from
Equation 2 to Equation 3. This is done in a stochastic manner as
explained in the next section. The expected absolute risk for people with
similar genetic/epigenetic characteristics is evaluated by multiplying the
RR by the average baseline incidence B for the subpopulation.
All model parameters and variables (including dose) are allowed to
vary over a heterogeneous population to account for variation in genet-
ic/epigenetic characteristics and variation in dose. When low doses of
low- and high-LET radiation are combined, low-LET radiation-related
ANP is assumed to be fully expressed (all protective pathways) except for
very low doses (near the natural background radiation level) as previous-
ly indicated. The number of individuals with ANP is modeled stochasti-
cally as varying with dose to allow for radiation dose-related episilencing
of adaptive-response genes promoters. 
Figure 2 presents a schematic representation of the revised HRR
model. The population average RR is plotted vs. the total absorbed dose D
for combined exposure to high-LET alpha and low-LET beta/gamma
radiation. Dose b is the radiation dose from natural background radiation
exposure for the period of interest. The dose indicated by “0” is for a
hypothetical environment without any natural background radiation.
The dose interval 0 to D* makes up Transition Zone A, where stochastic
thresholds (low-LET radiation component) for stimulating (e.g., epiacti-
FIGURE 2. Schematic representation of the cancer relative risk vs. dose relationships according to
the HRR model. See the text for explanation of the doses and zones. 
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vating) adaptive-response genes occur. The Zone of Maximal Protection
spans the range D* to D** where everyone is presumed to have low-LET
radiation ANP against cancer. The dose interval D** to D*** comprises
Transition Zone B, where stochastic thresholds for adaptive-response gene
promoter silencing (via episilencing and/or induced mutations) occur.
For doses just above D*** (Linear Zone) everyone is presumed to have
their adaptive response genes silenced. The additional linear increase at
higher doses (Linear Zone) relates to additional mutation inductions in
adaptive-response genes.
IMPLEMENTATION OF THE HRR MODEL
While there is currently little information available on the impact of
specific genetic/epigenetic characteristics on cancer risk, employing the
HRR model using Bayesian inference methods implemented with Markov
chain Monte Carlo (MCMC) allows the distributions (posterior) of model
parameters (and functions of the parameters such as RRANP and RRLNT) to
be generated. The distributions are expected to at least crudely reflect
the impacts of the varying genetic/epigenetic characteristics. The
Appendix briefly explains Bayesian inference methods and their imple-
mentation using MCMC.
A single very long chain (rather than shorter multiple chains) and
uniform prior distributions for model parameters were used for the
MCMC results presented in this paper. Chain lengths needed for conver-
gence were judged based on autocorrelations after the first 10,000 itera-
tions. The ratio of the posterior distribution Monte Carlo error to the
model parameter standard deviation <0.05 (for each parameter) was
judged to be consistent with convergence (Spiegelhalter et al. 2003). 
In our analyses of lung cancer dose-response data presented, rather
than using point estimates of dose, dose intervals were used that were
based on the experimental or epidemiological data fitted. Doses were
assumed uniformly distributed over the exposure-group-specific intervals
used because detailed information on dose variation over the reported
intervals was not available. Results obtained are therefore conditional on
the assumed dose distributions.
USING THE HRR MODEL TO DEMONSTRATE GAMMA-RAY PREVENTION
OF ALPHA-RADIATION-INDUCED LUNG CANCER IN THE WISTAR RAT
MODEL OF LUNG CANCER
Two studies were conducted by Sanders and colleagues that involved
inhalation exposure of Wistar rats to alpha-emitting aerosols of 239Pu
(Sanders 2008). One study used 239PuO2 alone (Table 2) and a second
study (Table 3) used a 169Yb2O3-
239PuO2 aerosol. Only data for alpha radi-
ation doses up to approximately 8000 mGy (8 Gy) are used here. The
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169Yb was used as a tracer to track how much 239Pu deposited in the lung
(via counting of 169Yb gamma rays). The 169Yb-emitted gamma rays are
capable of activating components of the natural protection system
already described (i.e., adaptive-response phenotypes). Gamma-ray doses
from 169Yb estimated to be 1–2 mGy delivered at very low rates over about
4 months appeared to have completely prevented alpha-radiation-
induced lung cancer (Sanders 2008; Scott et al. 2008).
We have fitted the revised HRR model to Sanders’ Wistar rat data
using Bayesian inference methods (see Appendix) implemented with
MCMC and results are presented in Figures 3 and 4 and Tables 2 and 3.
In our analyses we only included alpha radiation doses up to approxi-
TABLE 2. Frequency of lung tumors in female Wistar rats after inhalation of 239PuO2 Aerosols
(Sanders 2008)
Average 
Alpha Radiation Observed Bayesian Analysis Posterior 
Number Dose ± Standard Lung Tumor Distribution Mean 
of Rats Deviation (mGy) Incidence Incidence (2.5%, 97.5%)a
656 0 0.0015 0.0015 (9.8 × 10–4,2.0 × 10–3)
131 < 100b 0.015 0.0091 (0.0057,0.0138)
51 270 ± 120 0.078 0.05 (0.022,0.083)
26 780 ± 170 0.346 0.135 (0.081,0.21)
38 2,550 ± 1,320 0.447 0.446 (0.273,0.651)
16 6,800 ± 1,200 0.313 0.846 (0.547,1.0)
aPercentiles 2.5 % and 97.5% of the Bayesian analysis posterior distribution for the tumor inci-
dence based on the HRR model. Doses were assumed uniformly distributed over the interval (aver-
age – 1.5 standard deviations, average + 1.5 standard deviations). 
bMid-range dose used as an estimate of the average. A subjective upper bound of 20 mGy was used
as an upper bound for the standard deviation.
TABLE 3. Frequency of lung tumors in female Wistar rats following inhalation of 169Yb2O3-
239PuO2
Aerosols (Sanders 2008)
Average 
Alpha Radiation Average Observed Bayesian Analysis Posterior 
Number Dose ± Standard Gamma-ray Lung Tumors Distribution Mean 
of Rats Deviation (Gy) Dose (mGy) Incidence Incidence (2.5%, 97.5%)a
1052 0 0 0.00095 0.00164 (5.4 × 10–4,0.004)
1389 0.056 ± 0.020 0.9 0 0.00146 (6.8 × 10–4, 0.0027)
343 0.19 ± 0.09 1.8 0 0.00387 (0.00143, 0.00861)
145 0.62 ± 0.16 1.3 0 0.0146 (0.00744,0.0256)
58 2.32 ± 0.77 2.5 0.069 0.0627 (0.03, 0.11)
38 5.03 ± 0.60 5.0 0.212 0.135 (0.076,0.212)
18 7.99 ± 0.67 0.8 0.278 0.21 (0.12,0.33)
aPercentiles 2.5 % and 97.5% of the Bayesian analysis posterior distribution for the tumor inci-
dence based on the HRR model. Doses were assumed uniformly distributed over the interval (aver-
age – 1.5 standard deviations, average + 1.5 standard deviations). 
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mately 8,000 mGy (8 Gy) in an attempt to avoid presumed significant life-
shortening effects of higher doses. A single MCMC chain was run for
100,000 iterations with the first 80,000 results discarded (this is called
FIGURE 3. Lung cancer incidence in Wistar rats after inhalation exposure to the alpha radiation
source 239PuO2 (upper dashed LNT-based line) or 
239PuO2 labeled with a 
169Yb gamma-emitting tag
(data points and associated lower family of curves based on HRR model). The lower family of curves
comprise the Bayesian posterior mean (solid curve) and percentiles (dashed curves) 2.5% and
97.5%. The data used are from Sanders (2008).
FIGURE 4. Lower dose-portion of Figure 3 with approximate upper 95% confidence interval (trian-
gles) for an observed incidence of zero (diamonds) added. The upper confidence interval on data
points for a zero incidence is based on observing an incidence of zero with a probability of approxi-
mately 0.05 (which corresponds to an expected 3 cancer cases). With the assumed Poisson distribu-
tion, the probability of 0 events when the expected value is 3 is given by exp(-3) which equals 0.05
(rounded). The data point for the highest dose group is off scale and is not presented so that the
shape of the curve at low doses is clearer.
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burn-in). The ratio of the Monte Carlo error for each parameter relative
to the parameter standard deviation was <0.05, consistent with conver-
gence of the indicated long chain. In addition to posterior distribution
means, percentiles 2.5% and 97.5% of the posterior distributions were
also recorded. Results (posterior distribution mean and percentiles 2.5%
and 97.5%) for exposure to only alpha radiation are presented in Table
2. The upper dashed line in both Figures 3 and 4 is based on data for
exposure to alpha radiation alone (posterior distribution mean [estimate
of population average]). For the alpha-radiation-only line, the posterior
distribution mean for Kα (= 1.5 x 10
–4 ± 3.2 x 10–5 mGy–1) was used along
with a spontaneous cancer incidence of 0.0015. The alpha-radiation-only
data are excluded but are presented in Table 2 along with the modeling
results (Sanders 2008; Scott et al. 2008). The lower solid curve and upper
and lower dashed bands are the Bayesian posterior means and percentiles
2.5% and 97.5% based on the HRR model. Kα was constrained to be fixed
at 1.5 x 10–4 mGy–1 (posterior distribution mean for exposure to alpha
radiation only) for fitting of the data for combined alpha and gamma
irradiation. Thus, results for combined exposure to alpha and gamma
rays are conditional on this value for Kα. A high level of gamma-ray ANP is
implicated in the results, as PROFAC = 0.83 ± 0.04. This means that on aver-
age >80% of sporadic and hereditary lung cancers appear to have been
prevented by gamma-ray ANP. The indicated value for PROFAC is very
close to the posterior mean of 0.86 ± 0.07 we previously published for
gamma-ray ANP against 239Pu alpha radiation-induced lung cancer in
Mayak plutonium facility workers (Scott and Di Palma 2006).
The high level of gamma-ray ANP against alpha radiation induced
lung cancer implicated in Figure 3 is thought to relate to the low dose of
gamma rays being spread over several months. The low-LET gamma-ray
dose to the lung was delivered over about 4 months while the alpha radi-
ation dose accumulated over several years. Thus, the presumably gamma-
ray-induced protection appears to have lasted for more than a year after
delivery of the protracted gamma-ray dose, ruling out persistent DNA
repair, PAM process, and induced immunity as contributing to persistent
protection over more than a year. Similar lifetime protection was report-
ed in other in vivo studies (Mitchel 2007). Thus, there appears to be a
previously unrecognized chronic, low-dose, low-LET radiation-induced
protective epigenetic change (memory effect) in normal cells in vivo (the
majority of the irradiated cells in the lung) that persists over long periods
because 1–2 mGy gamma-ray doses delivered over a few months would
not be expected to sustain DNA repair (Collis et al. 2004) or the PAM
process or immune system signaling for more than a year after irradia-
tion. This points to low-dose gamma-ray stimulated epireprogramming of
adaptive-response genes as possibly playing a major role in long-term pro-
tection against cancer. 
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We speculate that the indicated protective change in protracted
gamma-irradiated Wistar rats may involve a gamma-ray-induced long-last-
ing epigenetic memory effect in adaptive-response genes so that should
future threatening damage occur in nuclear DNA, the damage is quickly
recognized (e.g., lower damage response threshold) and adaptive-
response genes are more rapidly up-regulated to respond to the damage.
The hypothesized novel form of radiation adaptation would help explain
why a large mutagenic dose alone that invokes substantial DNA repair
and stimulation of immune functions is more mutagenic than when the
same dose is preceded by a very small adapting dose of low-LET radiation
(which does not appear to invoke DNA repair, the PAM process, or immu-
nity [Day et al. 2007]).
In Sanders’ Wistar rat study (2008) involving combined exposure to
alpha and gamma radiations, alpha radiation doses above 10 Gy (10,000
mGy) efficiently induced lung cancer, but these exposures were not as
efficient as alpha radiation alone, suggesting that protection against can-
cer by low-doses of low-LET radiation was reduced by other changes, pos-
sibly changes involving differential episilencing of adaptive-response
genes (Belinsky 2004; Belinsky et al. 2004; Karpinets and Foy 2005). In
this context, epireprogramming of adaptive-response genes would
explain the hormetic dose response curve for low-LET or low- plus high-
LET radiation induced cancer: low doses produce epiactivation while high
doses produce episilencing of adaptive-response gene promoters.
EVIDENCE FOR RESIDENTIAL-RADON-ASSOCIATED ACTIVATION AND
SILENCING OF ADAPTIVE-RESPONSE GENES
Radon exposure in the home is considered by regulatory agencies,
such as the EPA, to be a health hazard mainly because body organs (espe-
cially the lung) are exposed to high-LET alpha radiation from radon
progeny. Recently, concern has been raised about radon emanating from
granite countertops. Low-LET beta particles and gamma rays are also
emitted by radon progeny, although radiation doses are much lower than
those for alpha radiation. While there is good evidence that small doses
of alpha radiation alone efficiently cause lung cancer (e.g., Figures 3 and
4 ), there is equally good evidence that when small doses of low-LET radi-
ation are also involved, the body’s natural defenses can be stimulated,
suppressing lung cancer occurrence (Figures 3 and 4).
More than twenty case-control studies of the lung cancer risk from
radon in homes have now been reported for North American, European,
and Chinese locations (Thompson et al. 2008). Generally these studies
reported increased risk of lung cancer. However, the study designs were
deficient in that they had little power for demonstrating odds ratios (OR)
< 1, i.e., a radiation adaptive or hormetic response, and were biased for
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demonstrating OR > 1, usually under the LNT assumption (Scott et al.
2008; Thompson et al. 2008).
Similar low-LET radiation protection against alpha-radiation-induced
lung cancer as presented in Figures 3 and 4 (a modeling result) is now
implicated in data from a recent epidemiological study of lung cancer
(Figure 5) associated with residential radon progeny exposure
(Thompson et al. 2008). The study used a novel design that corrected most
of the deficiencies (e.g., lowest exposure [reference] group having a wide
rage of exposures is a big problem) associated with other mentioned stud-
ies that did not find evidence for OR < 1, due to low power for such a
demonstration. The study was performed with 200 cases (58% male, 42%
female) and 397 controls matched on age and sex, all from the same
health maintenance organization. Emphasis was placed on accurate and
extensive year-long dosimetry with etch-track detectors in conjunction
with careful questioning about historic patterns of in-house mobility.
Conditional logistic regression was used to control for years of residency,
smoking, education, income, and years of job exposure to known or
potential carcinogens. The researchers were surprised to find the adjusted
OR less than 1 (Table 4), which is in good agreement with our HRR model. 
Under the HRR model, OR and RR have similar shapes and OR would
be expected to first decrease to < 1 and then remain below 1 for a range
of radiation doses (or radon concentrations) at a roughly fixed level as is
illustrated in Figure 2 for RR. At higher doses OR is expected to increase
to > 1 as illustrated in Figure 2 for RR. Based on the HRR model, the 4
FIGURE 5. Adjusted odds ratio for lung cancer in association with residential radon exposure based
on data from Thompson et al. (2008). Odds ratio was evaluated relative to radon concentration in the
range 0 to < 25 Bq m–3. Data points are plotted at the midrange of the data in Table 4 with an assigned
upper bound of 400 Bq m–3 for the highest exposure level. The dashed curves are based on the 95%
confidence values reported by Thompson et al. (2008). Data points were connected by straight lines.
The horizontal line marks an adjusted odds ratio equaling 1.
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consecutive data points in Figure 5 with OR < 1 (presumed Zone of
Maximal Protection) can be averaged to assess the significance of the adap-
tive response. Here OR is assumed to be normally distributed for the indi-
cated zone. The average obtained is 0.38 ± 0.14, which is significantly < 1
(p < 10–5). Thus, on average, lung cancer appears to be reduced by 1 - 0.38
= 0.62 (62%) for people residing in homes with radon concentrations
between 25 and 250 Bq m–3 (0.676 pCi L–1 and 6.76 pCi L–1) as compared
with those residing in homes with lower concentrations. The value of 0.62
can be taken as a lower bound on PROFAC when evaluated relative to the
complete absence of any radon in the home. Interestingly, the
Environmental Protection Agency’s action level for residential radon of 4
pCi L–1 (USEPA 1993) is in the indicated zone of suppressed lung cancer
risk. According to the agency, lifetime exposure of a population of 1000
persons at a level of 4 pCi L–1 could lead to 29 lung cancer cases if these
individuals are cigarette smokers (USEPA 1993). The corresponding
number for never smokers is 2 lung cancer cases. In contrast, PROFAC >
0.62 indicates that one would expect on average > 62% of spontaneous
and smoking related lung cancer cases to be prevented due to the low-
level radon exposure in the home (i.e., a protective effect). A similar level
of protection against lung cancer occurrence has been reported for
radon-exposed Colorado plateau uranium miners (Thomas et al. 1985;
USEPA 1993) but not for other miner populations (USEPA 1993). Study
design biases can prevent demonstrating cancer suppression after low-
level radiation exposure (Scott et al. 2008; Thompson et al. 2008).
Based on the results presented, we can therefore state that for people
residing in homes with a radon concentration in the range 25–250 Bq m–3
(0.676 − 6.76 pCi L–1), remediation of their homes to eliminate radon may lead
to a substantial increase in their lung caner risk! This finding provides a rea-
son to be cautious about making claims about lung cancers being caused
by radon emanating from granite countertops in the home. The radon
may actually be protective against cancer, depending on the total level of
radon in the home.
TABLE 4. Adjusted odds ratio for lung cancer and 95% confidence interval by residential radon
concentration category for Worchester County, Massachusetts study of Thompson et al. (2008)
Radon Concentration Adjusted Odds Ratio (95% Confidence Interval) 
in Bq m–3 [pCi L–1]a p value relative to odds ratio = 1
< 25 [< 0.7 (rounded)] 1.0 (reference group)
25 − < 50 [0.7 − 1.4] 0.53 (0.24, 1.13), p ≤ 0.1
50 − < 75 [1.4 − 2.0] 0.31 (0.13, 0.73), p ≤ 0.05
75 − 150 [2.0 − 4.1] 0.47 (0.2, 1.10), p ≤ 0.1
150 − < 250 [4.1 − 6.8] 0.22 (0.04, 1.13), p ≤ 0.1
≥ 250 [> 6.8] 2.50 (0.47, 13.46)
aEnvironmental Protection Agency Action Level = 4 pCi L–1.
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DISCUSSION
Lung cancer is the leading cause of cancer mortality in women and
men in the United States and now accounts for approximately 30% of all
cancer deaths (Belinsky 2004; Jemal et al. 2002). Further, it has been pro-
jected that by 2010, annual lung cancer deaths worldwide will climb to
about 1.5 million (Parkin et al. 2001). The advent of spiral computed
tomography (CT) has led to capabilities of detecting precancerous nod-
ules in the lung as small as 1 – 5 mm (Davis 1991). However, others
(Brenner and Hall 2007; Hall and Brenner 2008) have speculated, based
on risk extrapolation from atomic bomb survivors in Japan to the clinic
in the United States using the LNT model, that many future lung and
other cancers are being induced by current usage of CT scans. However,
because X-ray doses from single CT scans are in the range for ANP against
cancer, Scott et al. (2008) have pointed out that CT scans may actually
reduce rather than increase the cancer risk. 
We have provided evidence that protracted gamma-ray doses of 1–2
mGy (equivalent to 7 to 13 repeated chest X-rays) significantly prevented
lung cancer in 239Pu-exposed (via inhalation) Wistar rats (Sanders 2008).
A modest increase in low-LET radiation exposure just above the natural
background level is proposed to activate wide-spread, protective epige-
netic signaling among normal cells (a mild stress response). Because of
the stochastic nature of the interaction of radiation with cells, most cells
are not directly hit when the radiation dose is very low (e.g., 0.001 − 0.1
mGy). We speculate that via bystander signaling pathways, large numbers
of cells (e.g., normal cells) participate in the adaptive response through
mild stress-related epireprogramming. This reprogramming is thought to
prime the cells for heightened defense against a future, more threaten-
ing insult by a genotoxic agent.
H2AX, the histone guardian of the genome (Fernandez-Capetillo et al.
2004) may play an important role in the low-LET radiation adaptive
response. A role for H2AX phosphorylation has been demonstrated in cell
cycle checkpoints, DNA repair, regulated gene recombinant events, and
tumor suppression. An attractive model that may relate to radiation adapta-
tion was proposed by Fernandez-Capetillo et al. in which chromatin restruc-
turing mediated by H2AX phosphorylation serves to concentrate DNA
repair/signaling factors and/or tether DNA ends. If this process is induced
by low-dose radiation and if there is a memory for mounting this process in
the event of a later enhanced genomic stress (e.g., high dose of carcinogen),
more rapid and more efficient DNA repair might be expected to occur.
More rapid DNA repair was found for people residing in regions of high nat-
ural background low-LET radiation (Masoomi et al. 2006). 
For the Wistar rat study previously discussed where 1-2 mGy of gamma
rays (early dose) protected from later accumulating alpha radiation doses
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that built up over more than a year after delivery of the gamma-ray dose,
the gamma-ray exposure may have enhanced DNA repair capacity (epi-
genetic memory effect) for dealing with subsequent damage induced by
alpha radiation. The early gamma-ray dose may have provided additional
protection via stimulating the PAM process and immune functions.
High radiation doses and chronic exposure to high levels of cigarette
smoke are known to stimulate gene promoter hypermethylation in the
lung epithelium. Malignant transformation in the epithelium also occurs
after years of chronic, sustained genotoxic stress from agents such as
tobacco carcinogens (Damiani et al. 2008). Both genetic and epigenetic
changes in tumor suppressor and oncogenes are considered to be impor-
tant in the occurrence of malignant transformation and the development
of lung cancer. 
Reprogramming of genes via gene promoter hypermethylation now
rivals gene mutation in relation to lung cancer occurrence. More than 60
genes have been identified as being episilenced in lung cancer cells (Belinsky et al.
2006). We proposed that among these genes are adaptive-response genes
that are epiactivated by low doses of low-LET radiation and episilenced by
high doses of low- and high-LET radiation. We speculate that the propen-
sity of gene silencing increases as a dose of a carcinogenic agent increas-
es. Deleterious episilencing of genes (e.g., through methylation) can
occur at the very early stages of lung cancer both in histologic precursors
to adenocarcinoma and squamous cell carcinoma and in the bronchial
epithelium of heavy, long time smokers (Damiani et al. 2008). We hypoth-
esize that episilencing occurs in adaptive-response genes and are plan-
ning studies to validate this hypothesis. 
Studies already conducted at our Institute have shown that the methy-
lation of the p16 gene occurs in alveolar hyperplasia and basal cell hyper-
plasia, which are early precursors to adenocarcinoma and squamous cell
carcinoma, respectively (Belinsky et al. 2006). For cancer-free smokers,
methylation of the p16 gene has also been found in the bronchial epithe-
lium (Belinsky et al. 2006). Such changes are also likely after chronic
exposure to high-level radiation as occurred in underground uranium
mines and among workers at the Mayak plutonium production facility in
Russia during its early years of operation under the former Soviet Union.
We speculate that p16 plays an important role in radiation adaptation via
cell cycle regulation (e.g., facilitating DNA repair). Whether low doses of low-
LET radiation can stimulate demethylation of the p16 gene has not been examined.
The fact that low doses and dose rates of low-LET radiation can stim-
ulate protective processes that prevent lung cancers associated with alpha
irradiation suggests that low-dose-radiation ANP could prevent future cancers
in high risk groups (e.g., heavy long-term smokers). The fact that low doses
of low-LET radiation stimulate immunity against cancer suggests that
such doses could also be used in curing existing cancer (i.e., low-dose can-
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cer therapy). With respect to cancer prevention, factors such as age and
genetic characteristics of the irradiated individual would need to be taken
into consideration. There is some evidence that the efficiency of radia-
tion ANP against breast cancer increases as age increases above about 50
years of age (Scott et al. 2008). Similar age-related influences may also
apply for lung and other cancers. The increased efficiency is thought to
possibly relate in part to an increased efficiency of reprogramming of
adaptive-response genes as age increases. The increase may relate to the
increasing threat posed by rising levels of genomic instability with increas-
ing age. There is now evidence for increased silencing of promoter
regions of genes via hypermethylation in the colon with increasing age
(Issa et al. 1994; Ahuja et al. 1998; Chan et al. 2002; Herman and Baylin
2003). Regarding low-dose cancer therapy for lung and other cancers,
one would have to consider that ANP is age-dependent, transient (for
some components), and the different onsets and durations of the pro-
tective components (e.g., PAM process, stimulated immunity against can-
cer) have not been resolved. 
The fact that low-rate exposure to gamma rays over an extended peri-
od enhances the level of ANP suggests that the protective processes can
be repeatedly reactivated. This points to the use of multiple small doses
of low-LET radiation in cancer therapy. However, cancer cells resist
undergoing apoptosis, implicating a resistance to the PAM process and to
killing by components of the immune system. Thus, combined therapy
involving multiple low doses of low-LET radiation in combination with
multiple low doses of an agent that can sensitize cancer cells to undergo
apoptosis might effectively destroy cancer cells. 
A recent study by Schwarz et al. (2008) demonstrated that an adapting
dose of 30 mGy sensitized cancer cells (a human colorectal cancer cell
line) to killing by a subsequent large radiation dose. In contrast, Schwarz
et al. (2008) found that normal human cells (fibroblast) were made resist-
ant to cell killing by the subsequent large dose.
Research at our Institute has focused on sensitizing lung cancer cells
to undergo apoptosis via novel means such as blockage of nuclear factor-
κB and Akt (Wang et al. 2006, 2007, 2008; Chen et al. 2007; Ju et al. 2007).
A recent study demonstrated that concurrent blockage of cell survival sig-
naling pathways involving nuclear factor-κB and Akt was quite effective in
sensitized lung cancer cells to TNF-induced apoptosis (Wang et al. 2007).
This raises the possibility for combination lung cancer therapy that uses
low doses of low-LET radiation along with agents that suppress cancer cell
survival signaling pathways involving nuclear factor-κB and Akt. An added
benefit of low doses of low-LET radiation would be stimulation of immu-
nity against cancer cells and stimulation of the PAM process.
Human exposures to ionizing radiation are managed through an LNT-
based system of radiation protection. Effective dose limits govern accept-
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able levels of radiation exposure. Any amount of radiation adds to the
effective dose and therefore supposedly increases cancer risk. However, this
system essentially ignores natural radiation protection and in doing so can
lead to radiation-phobia associated casualties during radiological emergen-
cies. Based on the material discussed herein and elsewhere (Ketchum 1987;
Wolf et al. 1988; Wolff 1989, 1992, 1996; Luckey 1991; Mifune et al. 1992;
Hipp and Bauer 1997; Trosko 1998; Redpath et al. 2001; Liu 2003; Sakai et
al. 2003; Scott 2004, 2005, 2007, 2008; Jaworowski 2006; Bauer 2007; Day et
al. 2007; Feinendegen 2005; Sakai 2006; Scott and Di Palma 2006;
Feinendegen et al. 2007; Liu 2007; Mitchel 2007; Portess et al. 2007; ;
Strzelczyk et al. 2007; Cohen 2008; Rithidech and Scott 2008; Sanders 2008;
Sanders and Scott 2008; Scott et al. 2008; Tubiana 2008), there is a need for
a more scientifically valid, updated system of radiation protection that
allows for radiation ANP. However, current radiation protection organiza-
tions continue to promote the LNT-based system in spite of its problems
(Strzelczyk et al. 2007). Thus, it is unlikely that the LNT-based system of
radiation protection will be revised any time soon unless pressure to do so
comes from better informed members of the world community.
CONCLUSIONS
We humans are not radiation free entities. Each day each of us emit
within our bodies millions of beta particles. These emissions are more
likely beneficial than harmful, as over time they probably stimulate epi-
activation of our adaptive-response genes, making adaptive responses,
including DNA repair, more efficient.
The observation that 1–2 mGy of gamma-rays delivered to the lung of
the Wistar rat over several months having prevented alpha-radiation-
induced lung cancers for absorbed alpha radiation doses up to approxi-
mately 600 mGy delivered over more than a year is consistent with the
possibility that low doses and dose rates of gamma rays stimulate epire-
programming of adaptive-response genes that persist (memory effect) for
an extended period, allowing for rapid up-regulation of adaptive-
response genes (e.g., DNA repair genes) at later times when there is a
serious threat to the genome.
The rapid increase in lung cancer risk for alpha radiation doses above
about 10,000 mGy (10 Gy) combined with 1–2 mGy of gamma rays is con-
sistent with adaptive-response genes (tumor suppressors and other genes)
being episilenced via promoter and/or histone methylation and/or his-
tone deacetylation. 
Lifetime exposure to residential radon at the Environmental Protection
Agency’s action level of 4 pCi L–1 appears to be associated with on average a
> 60% reduction in lung cancer cases compared to the cases that would be
expected for a radon concentration < 0.7 pCi L–1 (25 Bq m–3).
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Low-dose, low-LET-radiation ANP along with other apoptosis-sensitiz-
ing agents (targeted to precancerous or cancerous cells) could be exploit-
ed in lung cancer prevention and lung cancer therapy; however, consider-
able research is needed in this area before clinical applications are likely.
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APPENDIX
Estimating HRR Model Parameters Using Bayesian Inference Implemented
with MCMC
With the Bayesian approach, model parameters and the biological
effects for data of interest (e.g., lung cancer incidence) are considered
random variables (Gamerman 1997; Siva, 1998; Miller et al. 2002). If
“data” is used to denote the observed biological effects vector and θ is used
to denote a model parameters vector, then formal Bayesian inference
requires setting up a joint probability distribution P(data,θ) over the quanti-
ties in the two vectors (cancer incidences and model parameters). This
joint distribution comprises two parts: a prior distribution, P(θ), and a
likelihood, P(data|θ). The vertical bar indicates that the data vector is
conditional on the parameter vector θ. The joint probability distribution
is specified as
P(data,θ) = P(data|θ)P(θ) = P(θ|data)P(data). (1)
Both P(θ) and P(data) are unconditional distributions. When new
observations are available, Bayes theorem is used to update the distribu-
tion of the parameters P(θ|data) given (i.e., conditional on) the new data.
The Bayesian updating relationship can be expressed as (Siva, 1998):
P(θ|data) = P(data|θ)P(θ)/∫ P(data|θ)P(θ)dθ = 
P(data|θ)P(θ)/P(data). (2)
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Depending on the complexities of the model being addressed, ana-
lytical solutions to Equation 2 may exist. For many exposure scenarios,
analytical solutions do not exist for complex stochastic model such as the
HRR model. Thus, for this model, the integral is estimated numerically
using MCMC (Gilks et al. 1996; Scott and Di Palma 2006).
MCMC methods are a group of sophisticated methods that are often
used in complex Bayesian analyses. The most common implementation
uses what are called the Metropolis-Hastings algorithm and Gibbs sam-
pling. Markov chains provide a framework under which simulation tech-
niques may be used to explore various distribution properties, generally
focused on the posterior distribution. Gibbs sampling is iterative and
allows the marginal distribution of model parameters (e.g., slope param-
eter and profac in the HRR model) to be directly sampled. The Markov
chain component of Gibbs sampling provides the framework from which
the random samples are generated. However, it is required that the dis-
tribution of all parameters, conditional on all other influential parame-
ters and the data fitted, to be specified to allow Monte Carlo sampling.
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